Press Releases
Palleon Pharmaceuticals Recognized as a Fierce Biotech “Fierce 15” Company for 2023
Palleon Pharmaceuticals Announces First Patient Dosed with E-602 in Combination with Cemiplimab in GLIMMER-01 Phase 1/2 Clinical Trial
Palleon Pharmaceuticals Presents Initial Phase 1 Results from the GLIMMER-01 Clinical Trial for E-602, the First Ever Glyco-Immune Checkpoint Inhibitor
Palleon Pharmaceuticals to Present at the Guggenheim Healthcare Talks Oncology Day
In the News
Introducing Fierce Biotech’s 2023 Fierce 15
Fierce Biotech
Meet 20 women leaders reshaping biopharma in 2023
Endpoints
Novel strategy of attacking sugars on cancer cells to free immune system shows promise in early tests
STAT
Palleon unveils PhI look at ‘lawn mower’ approach to glycoimmunology: #AACR23
Endpoints